Cargando…
Targeted therapy for localized non-small-cell lung cancer: a review
Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940012/ https://www.ncbi.nlm.nih.gov/pubmed/27462164 http://dx.doi.org/10.2147/OTT.S104938 |
_version_ | 1782442091126718464 |
---|---|
author | Paleiron, Nicolas Bylicki, Olivier André, Michel Rivière, Emilie Grassin, Frederic Robinet, Gilles Chouaïd, Christos |
author_facet | Paleiron, Nicolas Bylicki, Olivier André, Michel Rivière, Emilie Grassin, Frederic Robinet, Gilles Chouaïd, Christos |
author_sort | Paleiron, Nicolas |
collection | PubMed |
description | Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR, tyrosine kinase inhibitors have shown no efficacy in Phase III trials. Few data are available for EGFR-mutated localized NSCLC, as routine biological profiling is not recommended. Available studies are small, often retrospectives, and/or conducted in a single-center making it difficult to draw firm conclusions. Ongoing prospective Phase III trials are comparing adjuvant tyrosine kinase inhibitor administration versus adjuvant chemotherapy. By analogy with the indication of bevacizumab in advanced NSCLC, use of antiangiogenic agents in the perioperative setting is currently restricted to nonsquamous NSCLC. Several trials of adjuvant or neoadjuvant bevacizumab are planned or ongoing, but for the moment there is no evidence of efficacy. Data on perioperative use of biomarkers in early-stage NSCLC come mainly from small, retrospective, uncontrolled studies. Assessment of customized adjuvant or neoadjuvant therapy in localized NSCLC (with or without oncogenic driver mutations) is a major challenge. |
format | Online Article Text |
id | pubmed-4940012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49400122016-07-26 Targeted therapy for localized non-small-cell lung cancer: a review Paleiron, Nicolas Bylicki, Olivier André, Michel Rivière, Emilie Grassin, Frederic Robinet, Gilles Chouaïd, Christos Onco Targets Ther Review Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR, tyrosine kinase inhibitors have shown no efficacy in Phase III trials. Few data are available for EGFR-mutated localized NSCLC, as routine biological profiling is not recommended. Available studies are small, often retrospectives, and/or conducted in a single-center making it difficult to draw firm conclusions. Ongoing prospective Phase III trials are comparing adjuvant tyrosine kinase inhibitor administration versus adjuvant chemotherapy. By analogy with the indication of bevacizumab in advanced NSCLC, use of antiangiogenic agents in the perioperative setting is currently restricted to nonsquamous NSCLC. Several trials of adjuvant or neoadjuvant bevacizumab are planned or ongoing, but for the moment there is no evidence of efficacy. Data on perioperative use of biomarkers in early-stage NSCLC come mainly from small, retrospective, uncontrolled studies. Assessment of customized adjuvant or neoadjuvant therapy in localized NSCLC (with or without oncogenic driver mutations) is a major challenge. Dove Medical Press 2016-07-05 /pmc/articles/PMC4940012/ /pubmed/27462164 http://dx.doi.org/10.2147/OTT.S104938 Text en © 2016 Paleiron et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Paleiron, Nicolas Bylicki, Olivier André, Michel Rivière, Emilie Grassin, Frederic Robinet, Gilles Chouaïd, Christos Targeted therapy for localized non-small-cell lung cancer: a review |
title | Targeted therapy for localized non-small-cell lung cancer: a review |
title_full | Targeted therapy for localized non-small-cell lung cancer: a review |
title_fullStr | Targeted therapy for localized non-small-cell lung cancer: a review |
title_full_unstemmed | Targeted therapy for localized non-small-cell lung cancer: a review |
title_short | Targeted therapy for localized non-small-cell lung cancer: a review |
title_sort | targeted therapy for localized non-small-cell lung cancer: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940012/ https://www.ncbi.nlm.nih.gov/pubmed/27462164 http://dx.doi.org/10.2147/OTT.S104938 |
work_keys_str_mv | AT paleironnicolas targetedtherapyforlocalizednonsmallcelllungcancerareview AT bylickiolivier targetedtherapyforlocalizednonsmallcelllungcancerareview AT andremichel targetedtherapyforlocalizednonsmallcelllungcancerareview AT riviereemilie targetedtherapyforlocalizednonsmallcelllungcancerareview AT grassinfrederic targetedtherapyforlocalizednonsmallcelllungcancerareview AT robinetgilles targetedtherapyforlocalizednonsmallcelllungcancerareview AT chouaidchristos targetedtherapyforlocalizednonsmallcelllungcancerareview |